Why Starling Oncology, Inc. (STLN) stock fell 46.0% on Friday, November 6, 2026

Starling Oncology, Inc. (STLN) closed at $3.62, down 45.97% on Friday, November 6, 2026, on volume of 23,841,299 shares (17.3× its 3-month average); market value about $400.0M.

What happened: primary sources

Events Nexqual found for STLN on Friday, November 6, 2026 or the trading day before (November 5, 2026):

• Nov 5, 2026: Reported Q3 2026 results: EPS −$0.13 vs consensus −$0.05 (miss), revenue $169.8M vs consensus $168.7M (beat). Guidance: The company affirmed its full-year 2026 guidance for revenue, gross profit, adjusted EBITDA, and free cash flow. source
• Nov 6, 2026: B. Riley Securities: Target lowered, Buy, price target $11 → $10
• Nov 6, 2026: BTIG: Target raised, Buy, price target $9 → $10
• Nov 6, 2026: One of 4 Medical Care Facilities stocks among the day's biggest losers (STLN, AMN, BKD, ASTH), with no comparable group among the biggest gainers

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on STLN

STLN stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Earnings report: STLN results, November 5, 2026. Other big moves that day: November 6, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:31 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:31 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt